Nurix Therapeutics, Inc. NRIX
23.08
(0.57)
(2.41%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow NRIX
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
| P/S ratio | 9.16 | 17.45 | 24.24 | 52.54 | |
| P/FCF ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/Operating CF | (13.36) | (21.61) | (24.20) | (20.00) | |
| P/B ratio | 2.06 | 2.72 | 3.62 | 4.80 | |
| Price to Tangible BV | 2.06 | 2.72 | 3.62 | 4.80 | |
| EV/Sales | 4.04 | 10.39 | 16.71 | 40.48 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/Operating CF | (1.47) | (3.50) | (4.61) | (5.07) | |
| EV/FCF | (1.40) | (3.31) | (4.41) | (4.89) | |
| Quick Ratio | 5.21 | 6.86 | 5.86 | 6.16 | |
| Current Ratio | 5.35 | 7.02 | 6.01 | 6.34 | |
| Net Debt/EBITDA | 4.96 | 6.68 | 6.09 | 4.91 | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 0.16 | 0.12 | 0.11 | 0.07 | |
| Operating CF/Net income | 0.66 | 0.87 | 0.82 | 1.08 | |
| Capex/Depreciation | (0.54) | 0.90 | (0.28) | (0.50) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 1,090.96% | 611.50% | 1,345.76% | 969.29% | |
| Selling, General and Administrative Expense of Revenue | 166.70% | 100.52% | 233.69% | 172.44% | |
| Intangible Assets out of Total Assets | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Based Compensation of Revenue | 123.79% | 66.92% | 150.42% | 125.93% | |
| Graham Net Nets | 0.38 | 0.31 | 0.23 | 0.17 | |
| Graham Number | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Yield | (32.60%) | (17.98%) | (19.99%) | (19.84%) | |
| Free Cash Flow Yield | (31.48%) | (17.98%) | (15.62%) | (15.76%) | |
| Revenue per Share | 0.09 | 0.16 | 0.06 | 0.08 | |
| Operating CF per Share | (0.68) | (0.78) | (0.65) | (0.87) | |
| Capex per Share | (0.03) | (0.06) | (0.01) | (0.02) | |
| Free Cash Flow per Share | (0.71) | (0.84) | (0.66) | (0.89) | |
| Cash per Share | 5.10 | 6.84 | 4.91 | 3.99 | |
| Shareholders Equity per Share | 4.42 | 6.22 | 4.37 | 3.62 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 4.42 | 6.22 | 4.37 | 3.62 | |
| Free Cash Flow | (60.10) | (72.96) | (72.96) | (98.51) | |
| Working Capital | 358.25 | 520.35 | 462.20 | 384.46 | |
| Capital Expenditures | (2.71) | (5.13) | (1.04) | (1.94) | |
| Net Current Asset Value | 290.38 | 457.43 | 399.16 | 323.57 | |
| EV/EBIT | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capex to Sales | 0.34 | 0.38 | 0.17 | 0.21 | |
| Net Profit Margin | (1,094.77%) | (576.13%) | (1,394.34%) | (990.10%) | |
| Price to Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
| Average Payables | 6.26 | 11.35 | 9.35 | 9.08 | |
| Average Assets | 518.04 | 678.74 | 625.59 | 563.55 | |
| Average Common Equity | 374.55 | 532.87 | 480.91 | 425.12 |
Columns are period end dates